高级检索
    何友兼, 董秋美. 贝伐单抗一线治疗结直肠癌进展后二线应用的临床生存获益:来自于BRiTE的研究[J]. 循证医学, 2009, 9(3): 150-151. DOI: 10.3969/j.issn.1671-5144.2009.03.017
    引用本文: 何友兼, 董秋美. 贝伐单抗一线治疗结直肠癌进展后二线应用的临床生存获益:来自于BRiTE的研究[J]. 循证医学, 2009, 9(3): 150-151. DOI: 10.3969/j.issn.1671-5144.2009.03.017
    shu
    HE You-jian, DONG Qiu-mei. Clinical Overall Survival Benefit of Bevacizumab beyond First Progression in Colorectal Cancer: From BRiTE Study[J]. Journal of Evidence-Based Medicine, 2009, 9(3): 150-151. DOI: 10.3969/j.issn.1671-5144.2009.03.017
    Citation: HE You-jian, DONG Qiu-mei. Clinical Overall Survival Benefit of Bevacizumab beyond First Progression in Colorectal Cancer: From BRiTE Study[J]. Journal of Evidence-Based Medicine, 2009, 9(3): 150-151. DOI: 10.3969/j.issn.1671-5144.2009.03.017
    shu

    贝伐单抗一线治疗结直肠癌进展后二线应用的临床生存获益:来自于BRiTE的研究

    Clinical Overall Survival Benefit of Bevacizumab beyond First Progression in Colorectal Cancer: From BRiTE Study

      摘要
      • HTML全文
      • 参考文献(0)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回